Breast Cancer, Diagnostics and Screening
Read Time: 2 mins

Breast Cancer Screening in Older Women— Current Evidence and Future Perspectives

Copy Link
Published Online: May 6th 2015 Oncology & Hematology Review, 2015;11(1):34–5 DOI:
Authors: Nienke A de Glas, Gerrit-Jan Liefers
Quick Links:
Article Information

As populations of developed countries are aging, the number of older women with breast cancer will strongly increase. Randomized controlled trials in breast cancer screening rarely included patients over the age of 68. As a consequence, there is no solid evidence for beneficial effects of breast cancer screening in older women. In a recent observational study, we showed that the implementation of screening in women aged 70–75 in the Netherlands resulted in a strong increase of the incidence of early-stage breast cancer, while the incidence of advanced stage breast cancer barely decreased. Hence, current data do not support population-based screening in women over the age of 70.


Breast cancer screening, population-based screening, older patients


Breast cancer remains one of the largest contributors to cancer mortality in women in developed countries.1,2 As populations of developed countries are aging, the number of older women who have breast cancer will markedly increase in the upcoming decades. It has been shown that breast cancer prognosis deteriorates with age, even though mortality for other causes also increases with age.3 Beyond differences in treatment strategies, this may be explained by older women generally presenting at a much more advanced stage than their younger counterparts do.4

It has been assumed that earlier diagnosis of breast cancer through breast cancer screening (BCS) can improve prognosis, but population-based BCS has been heavily debated in the past decades.5–7 Large BCS trials on which current screening guidelines are based were generally performed in the 1980s and 1990s, and documented reductions in disease-specific mortality in randomized trials of screening are uncommon.8 Reductions in mortality for all causes are even more uncommon in single trials and have not been shown in the latest available meta-analysis of multiple trials.8 Of note, randomized controlled trials in BCS rarely included patients older than 68 years of age.9 Consequently, there is no solid evidence for beneficial effects of BCS in older women.

ome observational studies of BCS in older women have been published. Several have suggested that breast cancer survival is improved in patients who have screen-detected breast cancer, including older patients.10–13However, it is highly unlikely that this survival benefit can be explained by the actual screening, there being several forms of bias present in these type of studies, including lead-time bias, length-time bias, and selection bias.14

Alternatively, it is possible to assess the effects of BCS in observational studies without inducing these types of bias, by studying the incidence rates of early- and advanced-stage breast cancer.15 In a successful screening program, the incidence of early-stage breast cancer increases, whereas the incidence of advanced stage breast cancer decreases as a consequence of early detection.15 This method has been used several times in previous literature.15–17 In the Netherlands, the upper age limit of the mass BCS program was extended from 70 to 75 in 1998, enabling the use of this method to study the effects of screening in the Netherlands. It was shown that the incidence of early-stage breast cancer strongly increased, whereas the incidence of advanced stage breast cancer barely decreased.18 For every advanced-stage breast cancer prevented through screening, about 17 patients were overdiagnosed. Although long-term effects of toxicity and postoperative complications have not been studied in the older population, it is likely that this may result in significant loss of quality of life and physical functioning. These data thus do not support BCS on a population-based level.18

In past decades, the beneficial effect of screening has been communicated persistently to the public. But, however appealing, the adage “early diagnosis saves lives” may simply not be true, especially in older women. Accordingly, it will take a substantial effort to educate older women, as well as health professionals and policymakers, that age extension of mass screening programs may cause harm and is likely to be cost-ineffective. In the light of another adage—primum non nocere—it is an obligation we should not turn away from.

Article Information:

Nienke A de Glas, MD, and Gerrit-Jan Liefers, MD, PhD, have no conflicts of interest to declare. No funding was received in the publication of this article.


Gerrit-Jan Liefers, MD, PhD, Leiden University Medical Center, Department of Surgery, PO Box 9600 Postzone K6-R, 2300 RC Leiden, The Netherlands.

Open Access: This article is published under the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, adaptation, and reproduction provided the original author(s) and source are given appropriate credit.




  1. DeSantis C, Ma J, Bryan L, Jemal A, Breast cancer statistics, CA Cancer J Clin, 2014;64:52–62.
  2. Jemal A, Bray F, Center MM, et al., Global cancer statistics, CA Cancer J Clin, 2011;61:69–90.
  3. van de Water W, Markopoulos C, van de Velde CJ, et al., Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer, JAMA, 2012;307:590–7.
  4. Bastiaannet E, Liefers GJ, de Craen AJ, et al., Breast cancer in elderly compared to younger patients in the Netherlands: stage at diagnosis, treatment and survival in 127,805 unselected patients, Breast Cancer Res Treat, 2010;124:801–7.
  5. The Editors, When evidence collides with anecdote, politics, and emotion: breast cancer screening, Ann Intern Med, 2010;152:531–2.
  6. van Ravesteyn NT, Miglioretti DL, Stout NK, et al., Tipping the balance of benefits and harms to favor screening mammography starting at age 40 years: a comparative modeling study of risk, Ann Intern Med, 2012;156:609–17.
  7. Independent UK Panel on Breast Cancer Screening, The benefits and harms of breast cancer screening: an independent review, Lancet, 2012;380:1778–86.
  8. Gotzsche PC, Nielsen M, Screening for breast cancer with mammography, Cochrane Database Syst Rev, 2011;CD001877.
  9. Galit W, Green MS, Lital KB, Routine screening mammography in women older than 74 years: a review of the available data, Maturitas, 2007;57:109–19.
  10. Badgwell BD, Giordano SH, Duan ZZ, et al., Mammography before diagnosis among women age 80 years and older with breast cancer, J Clin Oncol, 2008;26:2482–8.
  11. Broeders MJ, Verbeek AL, Straatman H, et al., Repeated mammographic screening reduces breast cancer mortality along the continuum of age, J Med Screen, 2002;9:163–7.
  12. Otto SJ, Fracheboud J, Looman CW, et al., Initiation of population-based mammography screening in Dutch municipalities and effect on breast-cancer mortality: a systematic review, Lancet, 2003;361:1411–7.
  13. Otto SJ, Fracheboud J, Verbeek AL, et al., Mammography scr. Otto SJ, Fracheboud J, Verbeek AL, et al., Mammography screening and risk of breast cancer death: a populationbased case-control study, Cancer Epidemiol Biomarkers Prev, 2012;21:66–73.
  14. Cox B, Sneyd MJ, Bias in breast cancer research in the screening era, Breast, 2013;22:1041–5.
  15. Esserman L, Shieh Y, Thompson I, Rethinking screening for breast cancer and prostate cancer, JAMA, 2009;302:1685–92.
  16. Bleyer A, Welch HG, Effect of three decades of screening mammography on breast-cancer incidence, N Engl J Med, 2012;367:1998–2005.
  17. Helvie MA, Chang JT, Hendrick RE, Banerjee M, Reduction in late-stage breast cancer incidence in the mammography era: implications for overdiagnosis of invasive cancer, Cancer, 2014;120:2649–56.
  18. de Glas NA, de Craen AJ, Bastiaannet E, et al., Effect of implementation of the mass breast cancer screening programme in older women in the Netherlands: population based study, BMJ, 2014;349:g5410.

Further Resources

Share this Article
Related Content In Diagnostics and Screening
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72